Company profile

Ticker
OMCL
Exchange
CEO
Randall A. Lipps
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OMNICELL COM /CA/, OMNICELL INC /CA/
SEC CIK
IRS number
943166458

OMCL stock data

(
)

Calendar

31 Jul 20
27 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Omnicell earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
16 Sep 20 Randall A Lipps Common Stock Sell Dispose S Yes 76.145 300 22.84K 240,548
16 Sep 20 Randall A Lipps Common Stock Sell Dispose S Yes 75.6273 13,443 1.02M 240,848
15 Sep 20 Spears Joseph Brian Common Stock Payment of exercise Dispose F No 0 190 0 15,993
15 Sep 20 Randall A Lipps Common Stock Sell Dispose S Yes 75.0064 1,400 105.01K 254,291
6 Aug 20 Spears Joseph Brian Common Stock Grant Dispose A No 0 2,204 0 16,183
6 Aug 20 Spears Joseph Brian Stock Options NQ Common Stock Grant Aquire A No 68.04 6,301 428.72K 6,301
29 Jul 20 Randall A Lipps Common Stock Sell Dispose S Yes 75.1475 3,718 279.4K 148,398
29 Jul 20 Randall A Lipps Common Stock Sell Dispose S No 75.1475 3,718 279.4K 255,691
98.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 283 296 -4.4%
Opened positions 33 44 -25.0%
Closed positions 46 36 +27.8%
Increased positions 107 108 -0.9%
Reduced positions 113 106 +6.6%
13F shares
Current Prev Q Change
Total value 4.35B 3.84B +13.3%
Total shares 41.93M 40.35M +3.9%
Total puts 11.5K 2.9K +296.6%
Total calls 38.8K 32.3K +20.1%
Total put/call ratio 0.3 0.1 +230.1%
Largest owners
Shares Value Change
BLK BlackRock 6.59M $465.72M +2.5%
Wellington Management 5.24M $370M +44.7%
Vanguard 4.59M $324.49M +0.8%
CS Credit Suisse 1.66M $117.11M +14.9%
Conestoga Capital Advisors 1.5M $106.2M -9.7%
STT State Street 1.36M $96.1M +4.4%
Dimensional Fund Advisors 949.51K $67.05M -1.0%
BK Bank of New York Mellon 892.67K $63.04M +1.7%
Geneva Capital Management 863.41K $60.97M +2.7%
Eagle Asset Management 737.57K $50.63M -10.3%
Largest transactions
Shares Bought/sold Change
Wellington Management 5.24M +1.62M +44.7%
Arrowstreet Capital, Limited Partnership 303K +274.95K +980.1%
JHG Janus Henderson 252.08K +252.08K NEW
CS Credit Suisse 1.66M +214.68K +14.9%
Conestoga Capital Advisors 1.5M -161.91K -9.7%
BLK BlackRock 6.59M +160.3K +2.5%
IVZ Invesco 353.29K -129.13K -26.8%
Tygh Capital Management 32.95K -126.76K -79.4%
Citadel Advisors 0 -117.9K EXIT
FMR 102.09K +101.11K +10295.9%

Financial report summary

?
Risks
  • Unfavorable economic and market conditions, a decreased demand in the capital equipment market, and uncertainty regarding the rollout of government legislation in the healthcare industry could adversely affect our operating results.*
  • If we fail to develop new products or enhance our existing products to react to rapid technological change and market demands in a timely and cost-effective manner, or if more newly developed solutions, such as our XT Series, XR2 Automated Central Pharmacy System, and IVX Workflow, are not adopted in the same time frame and/or quantity as we anticipate, this could have a material adverse effect on our business, financial condition, and results of operations.*
  • We operate in highly competitive markets, and we may be unable to compete successfully against new entrants and established companies with greater resources and/or existing business relationships with our current and potential customers.*
  • The transition to selling more products which include a software as a service or solution as a service subscription presents a number of risks.
  • When we experience delays in installations of our medication management automation solutions or our more complex medication packaging systems, and such delays result in delays in our ability to recognize revenue, our competitive position, results of operations, and financial condition could be harmed.*
  • We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.
  • If we experience a significant disruption in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, our business could be adversely affected.*
  • We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.*
  • We may fail to realize the potential benefits of acquired businesses which could negatively affect our business, financial condition, and operating results.
  • If goodwill or other intangible assets that we recorded in connection with the Aesynt, Ateb, and InPharmics acquisitions, or have recorded in connection with prior acquisitions, become impaired, we could be required to take significant charges against earnings.
  • Changing customer requirements could decrease the demand for our products and services, and our new product solutions may not achieve market acceptance.
  • The healthcare industry faces changes to healthcare legislation and other healthcare reform, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
  • Government regulation of the healthcare industry could reduce demand for our products, or substantially increase the cost to produce our products.
  • Our software products are complex and may contain defects, which could harm our reputation, results of operations, and financial condition.
  • Our international operations may subject us to additional risks that can adversely affect our operating results.*
  • In the past, we have experienced substantial fluctuations in customer demand, and we cannot be sure that we will be able to respond proactively to future changes in customer demand.
  • Covenants in our A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and results of operations could be adversely affected.
  • If we are unable to recruit and retain skilled and motivated personnel, our competitive position, results of operations, and financial condition could be harmed.*
  • Our failure to protect our intellectual property rights could negatively affect our ability to compete.
  • Our quarterly operating results may fluctuate and may cause our stock price to decline.*
  • If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
  • If we are not able to supply the demand from our institutional and retail pharmacy customers on schedule and with quality consumable medication packaging products, or if we are otherwise unable to maintain our relationships with major institutional pharmacies, they may use alternative means to distribute medications to their customers and our revenue from sales of blister cards and other consumables may decline.*
  • If we are unable to successfully interface our automation solutions with the existing information systems of our customers, they may choose not to use our products and services.
  • We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.*
  • Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
  • If the market price of our common stock continues to be highly volatile, the investment value of our common stock may decline.*
  • The United Kingdom’s recent withdrawal from the European Union could adversely affect us.
  • Our U.S. government lease agreements are subject to annual budget funding cycles and mandated unilateral changes, which may affect our ability to enter into such leases or to recognize revenues, and sell receivables based on these leases.
  • If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
  • Intellectual property claims against us could harm our competitive position, results of operations, and financial condition.
  • Product liability claims against us could harm our competitive position, results of operations and financial condition.
  • We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
  • Complications in connection with our ongoing business information system upgrades, including those required to transition acquired entities onto information systems already utilized, and those implemented to adopt new accounting standards, may impact our results of operations, financial condition, and cash flows.
  • Outstanding employee stock options have the potential to dilute stockholder value and cause our stock price to decline.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, financial condition, and results of operations.*
  • Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business and financial condition.*
  • Catastrophic events may disrupt our business and harm our operating results.*
  • Anti-takeover provisions in our charter documents and under Delaware law, and any stockholders' rights plan we may adopt in the future, make an acquisition of us, which may be beneficial to our stockholders, more difficult.
Management Discussion
  • Product revenues represented 70% and 73% of total revenues for the three months ended June 30, 2020 and 2019, respectively. Product revenues decreased by $19.4 million, primarily due to the impact of the COVID-19 pandemic as health systems have been focusing resources on COVID-19 essential activities during the second quarter of 2020.
  • Services and other revenues represented 30% and 27% of total revenues for the three months ended June 30, 2020 and 2019, respectively. Services and other revenues include revenues from service and maintenance contracts, and rentals of automation systems. Services and other revenues increased by $1.6 million, primarily due to an increase in our installed customer base for our XT Series automated dispensing systems and IV solutions.
  • Our international sales represented 11% and 10% of total revenues for the three months ended June 30, 2020 and 2019, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: assistance, Attorney, BD, begun, JVM, lowest, NaN, premise, resume, resumed, ROWA, sequentially, STOCKART, surviving, TriaTech
Removed: AG, DIH, Knapp, Steuerungstechnik